Keep up to date with SBC’s latest newsletter … Read more
NRG Therapeutics shortlisted in this year’s Genesis 2022 BioNewsRound Award
Published on 5 Dec 2022
Attralus and Ossianix Announce an Option and License Agreement using the TXP1 Brain Shuttle for Targeted Delivery of AT-04, a Pan-Amyloid Removal Therapeutic, for Neurodegenerative Disorders
Published on 21 Nov 2022
GSK launches the Stevenage Giving Tree
Published on 14 Nov 2022
NRG Therapeutics Announces £16 million Series A to Advance Mitochondrial Therapeutics for Parkinsons and ALS
Published on 9 Nov 2022
Dr Sally Ann Forsyth OBE named in Cranfield University's Women to Watch 2022
Published on 8 Nov 2022
Stevenage Bioscience Catalyst leads with first digital kiosk in the UK from Merck
Published on 7 Nov 2022
GSK: New data show Shingrix can provide at least 10 years of protection against shingles in adults aged 50 years and over
Published on 21 Oct 2022
Thermo Fisher Scientific Launches Closed and Automated Cell Isolation and Bead Removal Solution to Help Evolve Cell Therapy Manufacturing
Published on 17 Oct 2022
Stevenage Bioscience Catalyst announces Marco Delise as new Entrepreneurship and Business Development Director
Published on 11 Oct 2022
Autifony to present preclinical data supporting the efficacy of its novel clinical-stage Kv3 modulators
Published on 7 Oct 2022
Achilles Therapeutics Co-founder Professor Charles Swanton to Participate in Expert Roundtable Highlighting Pivotal Nature of Neoantigens as Targets in Cancer Cell Therapy
Published on 6 Oct 2022
Cytiva strengthens cell line development with CEVEC acquisition
Published on 6 Oct 2022
Autolus Therapeutics Announces Collaboration with Bristol Myers Squibb for Use of Autolus’ Proprietary Safety Switch System
Published on 4 Oct 2022
Lab Hotel at Stevenage Bioscience Catalyst now fully booked
Published on 3 Oct 2022
Galecto: GB2064 Shows Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis, Validating LOXL2 as a Clinical Fibrosis Target
Published on 29 Sep 2022
LifeArc joins forces with Cystic Fibrosis Trust and Medicines Discovery Catapult to strengthen antimicrobial discovery efforts
Published on 28 Sep 2022
Stevenage Bioscience Catalyst: First science park in the UK to adopt Warp It equipment reuse scheme
Published on 22 Sep 2022
LifeArc: Promising new antibody treatment for osteoporosis and multiple sclerosis
Published on 20 Sep 2022
CGT Catapult begins Virtual Reality training to help ensure future workforce needs
Published on 20 Sep 2022
Revolo Biotherapeutics to Participate in the Sachs Associates 22nd Annual Biotech in Europe Forum for Global Partnering and Investment
Published on 16 Sep 2022
LifeArc portfolio company Ducentis BioTherapeutics acquired by Arcutis Biotherapeutics for up to $400 million
Published on 8 Sep 2022

Copyright © 2022 Stevenage Bioscience Catalyst

Designed and built by Onespacemedia

We use cookies to improve our site experience. Press accept to agree to our Cookie Policy. If you decline, your information won’t be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked.